Regulation of PD-L1 Expression by NF-κB in Cancer
Top Cited Papers
Open Access
- 25 November 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Immune checkpoints are inhibitory receptor/ligand pairs regulating immunity that are exploited as key targets of anti-cancer therapy. Although the PD-1/PD-L1 pair is one of the most studied immune checkpoints, several aspects of its biology remain to be clarified. It has been established that PD-1 is an inhibitory receptor up-regulated by activated T, B, and NK lymphocytes and that its ligand PD-L1 mediates a negative feedback of lymphocyte activation, contributing to the restoration of the steady state condition after acute immune responses. This loop might become detrimental in the presence of either a chronic infection or a growing tumor. PD-L1 expression in tumors is currently used as a biomarker to orient therapeutic decisions; nevertheless, our knowledge about the regulation of PD-L1 expression is limited. The present review discusses how NF-kappa B, a master transcription factor of inflammation and immunity, is emerging as a key positive regulator of PD-L1 expression in cancer. NF-kappa B directly induces PD-L1 gene transcription by binding to its promoter, and it can also regulate PD-L1 post-transcriptionally through indirect pathways. These processes, which under conditions of cellular stress and acute inflammation drive tissue homeostasis and promote tissue healing, are largely dysregulated in tumors. Up-regulation of PD-L1 in cancer cells is controlled via NF-kappa B downstream of several signals, including oncogene- and stress-induced pathways, inflammatory cytokines, and chemotherapeutic drugs. Notably, a shared signaling pathway in epithelial cancers induces both PD-L1 expression and epithelial-mesenchymal transition, suggesting that PD-L1 is part of the tissue remodeling program. Furthermore, PD-L1 expression by tumor infiltrating myeloid cells can contribute to the immune suppressive features of the tumor environment. A better understanding of the interplay between NF-kappa B signaling and PD-L1 expression is highly relevant to cancer biology and therapy.Funding Information
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Cariplo
- Ministero dell'Istruzione, dell'Università e della Ricerca
This publication has 149 references indexed in Scilit:
- NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide TreatmentPLOS ONE, 2013
- Return to homeostasis: downregulation of NF-κB responsesNature Immunology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growthOncogene, 2011
- NF-κB in immunobiologyCell Research, 2011
- ATM- and NEMO-Dependent ELKS Ubiquitination Coordinates TAK1-Mediated IKK Activation in Response to Genotoxic StressMolecular Cell, 2010
- Inflammation and EMT: an alliance towards organ fibrosis and cancer progressionEMBO Molecular Medicine, 2009
- Stabilization of Snail by NF-κB Is Required for Inflammation-Induced Cell Migration and InvasionCancer Cell, 2009
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Complex networks orchestrate epithelial–mesenchymal transitionsNature Reviews Molecular Cell Biology, 2006